Study identifier:NIS-ODE-FAS-2009/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An epidemiological prospective Cohort study to describe Treatment patterns of Fulvestrant And ExemeSTane in postmenopausal patients with advanced HR+ breast cancer under real-life conditions in GERmany
postmenopause
-
No
-
Female
570
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2014 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 1st-line Faslodex 500 mg | - |
Cohort 2 2nd-line Faslodex 500 mg | - |
Cohort 3 3rd- line Faslodex 500 mg | - |
Cohort 4 patients on exemestane | - |